Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary

J Rheumatol. 2019 Jul;46(7):751-754. doi: 10.3899/jrheum.180784. Epub 2019 Feb 1.


The use of immunosuppressive therapies for immune-mediated disease is associated with an elevated risk of infections and related comorbidities. While many infectious diseases can generally be prevented by vaccines, immunization rates in this specific patient population remain suboptimal, due in part to uncertainty about their efficacy or safety under these clinical situations. To address this concern, a multidisciplinary group of Canadian physicians with expertise in dermatology, gastroenterology, infectious diseases, and rheumatology developed evidence-based clinical guidelines on vaccinations featuring 13 statements that are aimed at reducing the risk of preventable infections in individuals exposed to immunosuppressive and immunomodulatory agents.


Publication types

  • Practice Guideline

MeSH terms

  • Adult
  • Autoimmune Diseases / drug therapy*
  • Canada
  • Humans
  • Immunocompromised Host*
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Infant
  • Infection Control / methods*
  • Inflammation / drug therapy
  • Patient Care Team
  • Vaccination / adverse effects*
  • Vaccination / methods*


  • Immunosuppressive Agents